AVADEL PHARMACEUTICALS-ADR logo

AVDL

AVADEL PHARMACEUTICALS-ADR

$9.3

Earnings Summary

Revenue
$0Mn
Net Profits
$-19.58Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

AVADEL PHARMACEUTICALS-ADR’s revenue fell -100% since last year same period to $0Mn in the Q2 2021. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated NaN% jump in its revenue since last 3-months.

Net Profits:

AVADEL PHARMACEUTICALS-ADR’s net profit fell -163.42% since last year same period to $-19.58Mn in the Q2 2021. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated -45.64% fall in its net profits since last 3-months.

Net Profit Margins:

AVADEL PHARMACEUTICALS-ADR’s net profit margin fell -Inf% since last year same period to -Inf% in the Q2 2021. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the AVADEL PHARMACEUTICALS-ADR post its latest quarter earnings

EPS Estimate Current Quarter
-0.22
EPS Estimate Current Year
-0.22

Highlights

EPS Estimate Current Quarter:

AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) estimates for the current quarter stand at -0.22 - a 26.27% jump from last quarter’s estimates.

EPS Estimate Current Year:

AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) estimates for the current year stand at -0.22.

Key Ratios

Key ratios of the AVADEL PHARMACEUTICALS-ADR post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the AVADEL PHARMACEUTICALS-ADR has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2023-03-07
-0.22
0
100%
2022-05-09
-0.44
-0.45
-3.14%
2022-11-09
-0.3
0
100%
2022-08-09
-0.41
-1.07
-160.15%

Company Information

Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Organisation
AVADEL PHARMACEUTICALS-ADR
Headquarters
10 Earlsfort Terrace, Dublin, Ireland, 2
Employees
66
Industry
Health Technology
CEO
Gregory Divis

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*